Psychedelic Spotlight News

  • Is Compass Pathways a GOOD INVESTMENT? (CMPS stock analysis)

    Listen, Videos

    In this episode, we take a deep dive into Compass Pathways (CMPS), a psychedelic-medicines company aiming to treat depression with psilocybin.

    To understand Compass Pathways (CMPS ), as a company and as an investment, you have to study 5 things:

    What problem is Compass Pathways trying to solve?
    CMPS’ clinical trial, treating depression with psilocybin
    The founders and leaders of Compass Pathways
    Compass’ Financials
    Is CMPS stock a good investment for a retail investor?

    As the psychedelic stocks sector takes off, Compass Pathways, alongside MindMed (MMED / MMEDF), looks poised to lead the pack. No other psychedelic-medicines company is as advanced in a clinical trial as is Compass Pathways (CMPS). CMPS has a phase 2b trial to test the effectiveness of psilocybin in treating Treatment-Resistant Depression could be game changing, and make for a great investment opportunity.
    Let me know in the comments what you guys think. Is Compass Pathways a GOOD INVESTMENT? Will the CMPS stock skyrocket in 2021?

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media!
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    Resources:
    https://compasspathways.com/

    https://www.webmd.com/depression/understanding-depression-basics#1

    https://www.psychiatry.org/patients-families/depression/what-is-depression

    https://www.nimh.nih.gov/health/statistics/major-depression.shtml

    https://www.webmd.com/depression/guide/depression-treatment-options#1

    https://www.ncbi.nlm.nih.gov/books/NBK361016/#:~:text=Inotherwordsantidepressantsare,foundtobeequallyeffective

    https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-019-2222-4#:~:text=Treatmentresistantdepression(TRD),MDDpatientpopulation1

    https://www.beckleyfoundation.org/psilocybin-for-depression-2

    https://www.hopkinsmedicine.org/news/newsroom/news-releases/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows

    https://compasspathways.com/our-research/psilocybin-therapy/about-psilocybin-therapy/#from-subnav

    https://psychedelicreview.com/person/ekaterina-malievskaia/

    https://compasspathways.com/team-member/george-goldsmith/
    https://compasspathways.com/team-member/lars-christian-wilde/

    https://www.reuters.com/article/us-compass-pathways-ipo/peter-thiel-backed-compass-pathways-files-for-u-s-ipo-idUSKBN25O31T

    https://www.globenewswire.com/news-release/2019/05/15/1825506/0/en/Anxiety-Disorder-and-Depression-Treatment-Market-To-Reach-USD-18-90-Billion-By-2026-Reports-And-Data.html

    https://www.treehugger.com/facts-about-magic-mushrooms-4868810
    https://psychedelicreview.com/person/ekaterina-malievskaia/

    #CompassPathways #CMPS #PsychedelicStocks #MindMed #MMED #MMEDF #PsychedelicStocks #ThePsychedelicInvestor